Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Gastric cancer
2016 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer
2006
EGFR Antagonists in Cancer Treatment
2008 Standout
The Performance of Risk Prediction Models
2008
Capecitabine: a novel agent for the treatment of solid tumors
2001
Pancreatic cancer
2004 Standout
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
Clinical translation of angiogenesis inhibitors
2002 Standout
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
2000
Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer
1999 Standout
Skin Toxic Effects of Polyethylene Glycol–Coated Liposomal Doxorubicin
2000
Cancer drug resistance: an evolving paradigm
2013 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
2003
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
2001 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
The biology of VEGF and its receptors
2003 Standout
Colorectal cancer prevention and treatment
2000
Safety and antitumor activity of recombinant soluble Apo2 ligand
1999 Standout
Cancer genes and the pathways they control
2004 Standout
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting
1994
Minimizing Long-Term Tumor Burden: The Logic for Metronomic Chemotherapeutic Dosing and its Antiangiogenic Basis
2003
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
2007
Adjuvant Therapy for Colon Cancer 2005: New Options in the Twenty-First Century
2006
Circos: An information aesthetic for comparative genomics
2009 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.
1994
A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer
2000
Endothelial cell effects of cytotoxics: balance between desired and unwanted effects
2004
Capecitabine: A review
2005
Apoptosis
2002 Standout
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin
2002
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer
1999
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Improving Adjuvant Therapy for Rectal Cancer by Combining Protracted-Infusion Fluorouracil with Radiation Therapy after Curative Surgery
1994
Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial
2002 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
2002 Standout
Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
1999
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
1998
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
Toxicology of antisense therapeutics
2004
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Tumorigenesis and the angiogenic switch
2003 Standout
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
2004
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Angiogenesis Research: Guidelines for Translation to Clinical Application
2001
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial
2003
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
2001
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
2002
Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
2005
Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer
2002
Combined Irinotecan and Oxaliplatin Plus Granulocyte Colony-Stimulating Factor in Patients With Advanced Fluoropyrimidine/Leucovorin-Pretreated Colorectal Cancer
1999
Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
2003
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297
2002
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
2000
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation
2006 StandoutScience
State-of-the-Art Therapeutics: Hodgkin's Lymphoma
2005
Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer
1999
Hodgkin's lymphoma
2003
Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
2008
The incidence of secondary leukemias.
1999
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
2004
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Works of J Pater being referenced
Comparing the predictive value of neural network models to logistic regression models on the risk of death for small-cell lung cancer patients
2005
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.
1998
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
1993
Influence of age on the treatment of limited-stage small-cell lung cancer.
1996
Dexamethasone (DEX) improves the efficacy of granisetron (GRAN) in the first 24 hours following high dose cisplatin (HDCP) chemotherapy
1993
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer.
1998
Modeling toxicity and response in carboplatin-based combination chemotherapy.
1994
Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy.
1986
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.
1998
Systemic Infusion Versus Bolus Chemotherapy with 5-Fluorouracil in Measurable Metastatic Colorectal Cancer
1992